| DIAMYD MEDICAL B |
| Schweden |
| Gesundheit |
| SE0005162880 / A1T90L |
| DMN (Frankfurt) |
| FRA:DMN, ETR:DMN, DMN:GR |
| - |
| https://www.diamyd.com/ |
|
Diamyd Medical AB is a biopharmaceutical company focused on developing therapies for diabetes. The primary aim of the company is to create innovative treatments, particularly concentrating on preserving insulin production in individuals with Type 1 d..
>Volltext.. |
| 18.17 Mio. EUR |
| 4.36 Mio. EUR |
| 0.03 Mio. EUR |
| -19.6 Mio. EUR |
| -19.17 Mio. EUR |
| -0.15 EUR |
| 4.1 Mio. EUR |
| 14.44 Mio. EUR |
| -15.56 Mio. EUR |
| 4.66 |
| 109.05% |
| -22.99% |
| - |
| - |
| - |
| - |
| DIAMYD |
| 06.04.26 |
|